In Vitro Inhibition of the Mycobacterium tuberculosis β-Ketoacyl-Acyl Carrier Protein Reductase MabA by Isoniazid
Open Access
- 1 January 2004
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 48 (1) , 242-249
Abstract
The first-line specific antituberculous drug isoniazid inhibits the fatty acid elongation system (FAS) FAS-II involved in the biosynthesis of mycolic acids, which are major lipids of the mycobacterial envelope. The MabA protein that catalyzes the second step of the FAS-II elongation cycle is structurally and functionally related to the in vivo target of isoniazid, InhA, an NADH-dependent enoyl-acyl carrier protein reductase. The present work shows that the NADPH-dependent β-ketoacyl reduction activity of MabA is efficiently inhibited by isoniazid in vitro by a mechanism similar to that by which isoniazid inhibits InhA activity. It involves the formation of a covalent adduct between Mn III -activated isoniazid and the MabA cofactor. Liquid chromatography-mass spectrometry analyses revealed that the isonicotinoyl-NADP adduct has multiple chemical forms in dynamic equilibrium. Both kinetic experiments with isolated forms and purification of the enzyme-ligand complex strongly suggested that the molecules active against MabA activity are the oxidized derivative and a major cyclic form. Spectrofluorimetry showed that the adduct binds to the MabA active site. Modeling of the MabA-adduct complex predicted an interaction between the isonicotinoyl moiety of the inhibitor and Tyr185. This hypothesis was supported by the fact that a higher 50% inhibitory concentration of the adduct was measured for MabA Y185L than for the wild-type enzyme, while both proteins presented similar affinities for NADP + . The crystal structure of MabA Y185L that was solved showed that the substitution of Tyr185 induced no significant conformational change. The description of the first inhibitor of the β-ketoacyl reduction step of fatty acid biosynthesis should help in the design of new antituberculous drugs efficient against multidrug-resistant tubercle bacilli.Keywords
This publication has 37 references indexed in Scilit:
- Mn(III) Pyrophosphate as an Efficient Tool for Studying the Mode of Action of Isoniazid on the InhA Protein of Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 2002
- Crystal Structure of MabA from Mycobacterium tuberculosis, a Reductase involved in Long-chain Fatty Acid BiosynthesisJournal of Molecular Biology, 2002
- Mycolic acid biosynthesis and enzymic characterization of the β-ketoacyl-ACP synthase A-condensing enzyme from Mycobacterium tuberculosisBiochemical Journal, 2002
- The X-ray structure of Brassica napus β-keto acyl carrier protein reductase and its implications for substrate binding and catalysisStructure, 2000
- The mabA gene from the inhA operon of Mycobacterium tuberculosis encodes a 3lketoacyl reductase that fails to confer isoniazid resistanceMicrobiology, 1998
- Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosisScience, 1998
- Enzymic Characterization of the Target for Isoniazid in Mycobacterium tuberculosisBiochemistry, 1995
- The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosisNature, 1992
- Drug-resistant TB may bring epidemicNature, 1992
- Control Mechanisms for Fatty Acid Synthesis in Mycobacterium Smegmatis1977